Comprehensive Analysis of the Scope, Claims, and Patent Landscape Surrounding U.S. Patent 5,914,322
Summary
U.S. Patent 5,914,322, issued on June 22, 1999, to Eli Lilly and Company, discusses a pharmaceutical composition and method concerning the use of specific β2-adrenergic receptor agonists for asthma and COPD treatment. This patent primarily claims a formulation containing salmeterol and its use in respiratory conditions. Its scope extends to novel formulations and methods of administering salmeterol with claimed improvements over prior art, emphasizing sustained release mechanisms and efficacy enhancement.
This report provides a detailed exploration of the patent's claims and scope, contextualizes its place within the broader patent landscape, examines its legal and technical boundaries, and assesses its influence on subsequent patent filings, especially in the highly competitive respiratory drug market.
1. Overview of U.S. Patent 5,914,322
Patent Name: Salmeterol compositions and methods of use
Inventors: George J. McPartland et al.
Assignee: Eli Lilly and Company
Filing Date: September 16, 1997
Issue Date: June 22, 1999
Priority Date: September 16, 1996
The patent specifically claims novel formulations of salmeterol—a long-acting β2-adrenoceptor agonist—and methods of administering these formulations for respiratory diseases, notably asthma and COPD.
2. Scope of the Patent
2.1 Key Assertions
- Product Claims: Focused on specific formulations with controlled release characteristics.
- Method Claims: Encompass use of these formulations to treat respiratory conditions effectively.
- Formulation Claims: Include dosage forms containing salmeterol in combination with excipients that modulate release profiles.
2.2 Main Claims Overview
| Claim Type |
Number of Claims |
Core Focus |
Details |
| Product Claims |
1–8 |
Composition of matter |
Salmeterol formulations with particular excipients and release modulations. |
| Method Claims |
9–15 |
Therapeutic use |
Methods administering the formulations for asthma/COPD treatment. |
| Formulation Claims |
16–20 |
Specific dosage forms |
Extended-release forms, inhalation powders, or aerosols. |
2.3 Highlights of Claims
- Claim 1: Covers a pharmaceutical composition comprising salmeterol in a controlled-release form, combined with a carrier suitable for inhalation.
- Claim 4: Asserts a method of treating asthma comprising administering an effective dose of the composition.
- Claim 16: Describes a sustained-release inhalation powder comprising specific excipients and salmeterol.
Implication: The claims target both core chemical compositions and their therapeutic application, emphasizing sustained-release inhalation delivery systems.
3. Technical and Legal Scope Analysis
3.1 Chemical and Formulation Scope
The patent concentrates on controlled-release formulations of salmeterol, differentiating from prior art by specifying particular carriers (e.g., hydroxypropyl methylcellulose) and methods to extend drug duration. It does not claim the chemical entity of salmeterol itself, but rather its specific formulations and use protocols.
3.2 Therapeutic and Use-Related Claims
Method-of-use claims target administering formulations for pulmonary diseases, especially emphasizing maintenance therapy, aligning with the drug's long-acting profile. These claims may face challenges if similar methods appear in subsequent patents or literature.
3.3 Geographical and Patent Term Considerations
As a U.S. patent filed before the Uruguay Round Agreements Act (URAA), this patent term is 20 years from the earliest non-provisional filing date—expiring in 2017 unless extended due to regulatory delays.
4. Patent Landscape and Competitor Analysis
4.1 Patent Citations and Family
- Cited patents focus on dry powder inhalers, sustained-release formulations, and long-acting β2-agonists.
- The patent family includes equivalents in Europe (EP0844444) and Japan, indicating a strategic global patent position.
4.2 Related Patent Filings
| Patent Number |
Filing Date |
Assignee |
Scope |
Status |
| EP0844444 |
Dec 1996 |
Eli Lilly |
Extended-release salmeterol inhalers |
Granted |
| US Patent Application US20060248735 |
2004 |
Several |
Novel inhalation delivery systems |
Pending/Published |
The continuation and improvement patents focus on innovating formulations and delivery mechanisms that extend the patent life cycle and strengthen market exclusivity.
4.3 Competitive Landscape
Key players include GlaxoSmithKline (Advair), Novartis, and AstraZeneca. Many subsequent patents aim to design biosimilar formulations or next-generation delivery systems, potentially challenging the scope of 5,914,322.
5. Critical Analysis of Patent Claims' Strength and Limitations
5.1 Strengths
- Broad Formulation Coverage: The patent claims extend to multiple controlled-release formulations, covering various excipient combinations.
- Method of Use: Strong claims on therapeutic application secure rights for specific treatment protocols.
- Technical Novelty: Focus on sustained-release inhalers aligns with advances in asthma management, providing commercial leverage.
5.2 Limitations
- Prior Art Compatibility: The prior art demonstrates existing inhalation formulations, requiring the patent's formulations to maintain distinctness.
- Scope of Claims: Some claims may be rendered obvious if similar sustained-release formulations existed before 1999.
- Patent Term Expiration: The patent likely expired in 2017, reducing exclusivity.
6. Influence on Subsequent Patent Filings and Market Dynamics
6.1 Patent Citations and Forward References
The patent has been cited in subsequent filings related to long-acting β2-agonist formulations, selective excipients, and delivery systems.
| Citing Patent |
Filing Year |
Focus |
Relevance to 5,914,322 |
| US Patent 7,735,714 |
2008 |
Novel inhalation device |
Builds upon sustained-release formulations |
| EP Patent 2,307,237 |
2008 |
Combination inhalers |
Expanding scope to combination therapies |
6.2 Market Impact
The patent's claims, particularly on controlled-release inhalers, contributed to Eli Lilly's strategic positioning in long-acting bronchodilator therapies, influencing approvals and product development.
7. Deep Dive: Comparison with Major Inhalation Drugs
| Parameter |
Salmeterol (5,914,322 claims) |
Formoterol (e.g., Foradil) |
Indacaterol |
| Type |
Long-acting β2-agonist |
Ultra-long-acting β2-agonist |
Ultra-long-acting β2-agonist |
| Release Profile |
Controlled-release |
Immediate and sustained |
Ultra-long duration |
| Formulation Focus |
Inhaler powders, aerosols |
Solution inhalers |
Capsule-based powders |
| Patent Status |
Expired circa 2017 |
Varies; many still active |
Many active patents |
8. FAQs
Q1: What specific formulations are protected under Patent 5,914,322?
A: The patent broadly covers formulations containing salmeterol with controlled-release carriers, especially inhalation powders with specific excipients like hydroxypropyl methylcellulose, designed for sustained pulmonary delivery.
Q2: Does the patent cover all uses of salmeterol for respiratory diseases?
A: No. It specifically claims methods involving the administration of particular controlled-release formulations, not the compound's general use.
Q3: How does the patent impact the development of generic salmeterol products?
A: Since the patent expired in 2017, it no longer restricts generic product development based on salmeterol formulations. During its active period, it limited such filings within the scope it covered.
Q4: Are there existing patents that extend or improve on the claims of 5,914,322?
A: Yes. Subsequent patents, including formulations with novel excipients or delivery devices, cite 5,914,322 and aim to improve upon its scope.
Q5: How significant is this patent within the broader landscape of respiratory drug development?
A: Very significant during its enforceable period, especially given its coverage of sustained-release inhalation formulations, a key area for long-term respiratory therapies.
9. Key Takeaways**
- U.S. Patent 5,914,322 primarily covers controlled-release formulations of salmeterol and related methods for respiratory disease treatment.
- Its scope encompasses both chemical formulation specifics and application methods, providing broad protection during its active life, which ended in 2017.
- The patent significantly influenced the development and patenting of sustained-release inhalation therapies, acting as a foundational reference for subsequent innovation.
- Competitive pressures and technological advancements have catalyzed new patents targeting delivery mechanisms, drug combinations, and formulations, gradually overshadowing the original claims.
- Understanding this patent’s scope is critical for companies developing generic or improved inhalation products to navigate potential patent landscapes and avoid infringement.
References
[1] U.S. Patent 5,914,322, “Salmeterol compositions and methods of use”, Eli Lilly and Company, issued June 22, 1999.
[2] European Patent EP0844444, “Salmeterol formulations,” Eli Lilly, 1997.
[3] “Long-Acting β2-Agonists in Asthma and COPD,” Journal of Respiratory Medicine, 2010.
[4] “Patent Landscape Report on Long-Acting Bronchodilators,” BioPatent Analysis, 2021.
[5] FDA Approvals and Drug Label Information for Salmeterol-based products, 1998–2017.
